Safety and immunological evaluation of NY-ESO-1 plasmid DNA (pPJV7611) cancer vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor type known to express NY-ESO-1 or LAGE-1 antigen
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 24 Dec 2009 Planned number of patients changed from 12 to 18 as reported by M.D. Anderson Cancer Center.
- 22 Aug 2007 Biomarkers information updated
- 21 Aug 2007 Status changed from in progress to completed.